Financials data is unavailable for this security.
View more
Year on year OncoTherapy Science Inc 's revenues fell -46.24%from 1.13bn to 610.12m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 15.15% reduction in net income from a loss of 1.12bn to a larger loss of 1.29bn.
| Gross margin | -32.12% |
|---|---|
| Net profit margin | -234.61% |
| Operating margin | -230.75% |
| Return on assets | -82.71% |
|---|---|
| Return on equity | -116.07% |
| Return on investment | -106.53% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at OncoTherapy Science Inc fell by 589.98m. Cash Flow from Financing totalled 671.37m or 110.04% of revenues. In addition the company used 1.23bn for operations while cash used for investing totalled 33.35m.
| Cash flow per share | -2.47 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.68 |
|---|---|
| Tangible book value per share | 3.68 |
More ▼
Balance sheet in JPYView more
| Current ratio | 3.55 |
|---|---|
| Quick ratio | 3.11 |
| Total debt/total equity | 0.0789 |
|---|---|
| Total debt/total capital | 0.0731 |
More ▼
